论文部分内容阅读
目的:探讨低分子肝素治疗肺心病心力衰竭的临床效果。方法:选择2009年7月～2010年5月在我所治疗的90例肺心病伴心力衰竭患者,随机分为治疗组(45例)和对照组(45例),对照组用常规方法治疗,治疗组在此基础上加用低分子肝素,比较两组疗效。结果:治疗组显效率为75.6%,有效率为17.8%,治疗总有效率为93.4%;对照组显效率为57.8%,有效率为15.6%,治疗总有效率为73.4%。两组治疗总有效率比较,差异有统计学意义(χ2=7.465,P<0.05),治疗组总体疗效优于对照组。结论:低分子肝素治疗肺心病心力衰竭效果显著,值得临床推广应用。
Objective: To investigate the clinical effect of low molecular weight heparin on heart failure of pulmonary heart disease. Methods: From July 2009 to May 2010, 90 patients with pulmonary heart disease and heart failure treated in our hospital were randomly divided into treatment group (45 cases) and control group (45 cases). The control group was treated by conventional method, On the basis of the treatment group, low molecular weight heparin was added, and the curative effect was compared between the two groups. Results: The effective rate of the treatment group was 75.6%, the effective rate was 17.8%, the total effective rate was 93.4%. The effective rate of the control group was 57.8%, the effective rate was 15.6% and the total effective rate was 73.4%. The two groups of total effective rate comparison, the difference was statistically significant (χ2 = 7.465, P <0.05), the overall efficacy of the treatment group was better than the control group. Conclusion: Low molecular weight heparin is effective in treating heart failure due to cor pulmonale and deserves clinical application.